ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2554

Inhibition of IL6 Receptor Improves Arthritis and Atherosclerosis in a Mouse Model of Rheumatoid Arthritis

Amy Archer1, Carla Cuda2, Alexander Shaffer2, Emily Alex Waters3, Chad Haney4, Rana Saber2, George Kenneth Haines III5, Jason Low6 and Harris R. Perlman7, 1Rheumatology, Northwestern University, Chicago, IL, 2Northwestern University, Chicago, IL, 3Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, 4Center for Advanced Molecular Imaging, Northwestern University, Evanston, IL, 5Mount Sinai, New York, NY, 6Genentech, San Francisco, CA, 7Feinberg School of Medicine, Northwestern University, Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis is a chronic, systemic, autoimmune disease associated with an increased risk of cardiovascular disease.  However, it is unclear what role patients’ dyslipidemia plays in enhancing this cardiovascular risk.  Moreover, the impact that treatments for rheumatoid arthritis have on both dyslipidemia and cardiovascular disease is under investigation. Anti-IL6 receptor (aIL6R) therapy is an effective treatment for rheumatoid arthritis but can be associated with an unfavorable lipid profile.  Our study examines whether treatment with aIL6R is able to improve both inflammatory arthritis and early atherosclerosis in a mouse model of rheumatoid arthritis (K/BxAg7). 

Methods: K/BxAg7mice on a high fat diet were treated with a murine aIL6R monoclonal antibody (cMR16-1) three times a week for 12 weeks.  Arthritis was histologically assessed by a blinded pathologist and with SPECT/CT.  Atherosclerosis was determined with whole mount sudan IV staining, sections though the aortic root and MRI.  Serum cholesterol levels and cytokine levels were determined via enzymatic and luminex assays respectively. 

Results: Our data show that cMR16-1 improves both articular and extra-articular inflammation, but does not influence bone resorption.  In addition, sudan IV staining showed a decrease in the area of early atherosclerosis by 30%.  As expected there was an associated increase in serum IL6.  We also observed an increase in adiponectin, leptin, VEGF and RANTES, as well as a decrease in GRO-alpha.  However, in our model treatment with cMR16-1 was not associated with any changes in the lipid profile of the K/BxAg7mice.

Conclusion: Thus our data suggest that cMR16-1 is able to improve arthritis and early atherosclerosis in the absence of changes to the lipid profile in our mouse model of rheumatoid arthritis.  This suggests that changes to the standard lipid profile may not be the ideal parameter to monitor in assessing the ability of treatments for rheumatoid arthritis to improve atherosclerosis.


Disclosure: A. Archer, None; C. Cuda, None; A. Shaffer, None; E. A. Waters, None; C. Haney, None; R. Saber, None; G. K. Haines III, None; J. Low, Genentech and Biogen IDEC Inc., 3; H. R. Perlman, None.

To cite this abstract in AMA style:

Archer A, Cuda C, Shaffer A, Waters EA, Haney C, Saber R, Haines GK III, Low J, Perlman HR. Inhibition of IL6 Receptor Improves Arthritis and Atherosclerosis in a Mouse Model of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/inhibition-of-il6-receptor-improves-arthritis-and-atherosclerosis-in-a-mouse-model-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-il6-receptor-improves-arthritis-and-atherosclerosis-in-a-mouse-model-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology